CAMBRIDGE, England, Nov. 4, 2022 /PRNewswire/ -- CellCentric, a privately owned, clinical stage biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces that the Chief Investigator of its haematological malignancies programme, Professor Tim Somervaille, will be presenting compelling pre-clinical and early phase clinical activity data for inobrodib (CCS1477) at the American Society of Haematology (ASH) Annual Meeting and Exposition 2022, in New Orleans on the 9-13th December.
CAMBRIDGE, England, April 6, 2022 /PRNewswire/ -- CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces the appointments of Kris Frese as Director of Cancer Biology, and Andrew Hughes, who joins the Board as a Non-Executive Director. Both have stellar experience and track records in oncology research and development.
CAMBRIDGE, England, Jan. 26, 2022 /PRNewswire/ -- CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces it has received funding from BrightEdge, the impact venture capital fund of the American Cancer Society. The funding will be used to further progress the clinical development of its ground-breaking, targeted treatment, inobrodib (formerly known as CCS1477) and are accompanied by additional significant investment from existing lead investor, Morningside Investments Limited.